+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Spinal Muscular Atrophy Treatment Market Size, Share & Trends Analysis Report By Type, By Treatment, By Route of Administration, By Region, And Segment Forecasts, 2025 - 2030

  • PDF Icon

    Report

  • 100 Pages
  • December 2024
  • Region: Global
  • Grand View Research
  • ID: 4700902

Spinal Muscular Atrophy Treatment Market Growth & Trends

The global spinal muscular atrophy treatment market size is expected to reach USD 13.09 billion by 2030, registering a CAGR of 18.0% from 2025 to 2030. This growth can be attributed to the increasing product approval and launches. For instance, in August 2020, the Food and Drug Administration approved Evrysdi (risdiplam) developed by Genentech, Inc., for the treatment of pediatric patients aged two months and older with spinal muscular atrophy (SMA).

In addition, in May 2020, Novartis AG received conditional approval to its SMA candidate Zolgensma (onasemnogene abeparvovec) from the European Commission (EC) to treat patients with SMA. It is only approved gene therapy in Europe. In March 2021, PTC Therapeutics, Inc., received marketing approval for Evrysdi (risdiplam) from the EMA for the treatment of patient with type1, 2, and 3 spinal muscular atrophy. Thus, increasing number of product approvals is expected to drive the spinal muscular atrophy treatment market.

Novartis AG is supporting SMA patients by offering medicine at free of cost through global Managed Access Program (MAP). This program provides 100 doses of Zolgensma at free of charge to eligible SMA patients across continents including North America, South America, Asia, Australia, Europe, and Africa. Thus, presence of such supportive programs for Zolgensma strengthens promotional activities and also aid in generating revenue.

Global SMA newborn screening and easy access to diagnostic tools should be included in routine approach. This would ensure early diagnosis and timely access to treatment. For instance, in July 2021, a charlotte baby received a breakthrough gene therapy treatment for Spinal Muscular Atrophy (SMA) at UNC Medical Center in Chapel Hill, N.C., after diagnosis with spinal muscular atrophy through Early Check newborn screening program. Such screening programs are expected to boost early diagnosis and treatment of disease.

Moreover, there are several extensive research collaborations undertaken by pharmaceutical companies with research institutes for developing novel therapies for the treatment of spinal muscular atrophy patients. For instance, in March 2021, PTC Therapeutics, Inc., and The Spinal Muscular Atrophy Foundation entered into research collaboration to advance scientific research and developing new treatment to treat patients with SMA.

However, high costs associated with the treatment and low availability of participant for clinical trial purposes may restrain market growth over the forecast period. The high cost related to research and development of an orphan drug is a major factor of rising prices of product. For instance, the most commonly used drug Spinraza costs around USD 125,000 per injection and USD 750,000 annually. Furthermore, Zolgensma (AVXS-101) costs USD 2.1 million for one time treatment.

Spinal Muscular Atrophy Treatment Market Report Highlights

  • By type, the type-1 segment held the largest market share in 2024 due to higher prevalence and wide availability of products for the treatment of patients with type-1 spinal muscular atrophy
  • By treatment, the gene therapy segment is expected to be the fastest growing segment over the forecast period due to increase market penetration. Zolgensma is the only approved gene therapy in 37 countries to treat patient with SMA
  • By drug, the Spinraza segment dominated the market in 2024 due to presence of supportive reimbursement policies and increasing awareness about products. Currently, Spinraza is applicable for full reimbursement in three European countries Italy, Norway, Netherlands
  • By route of administration, the injection segment dominated the market in 2024 due to high safety, efficacy, and tolerability associated with infusion drugs to SMA patients through this route of administration
  • Asia Pacific is expected to be the fastest growing region during the forecast period. The growth of region is attributable to the entry of new products into the region. For instance, in July 2021, F. Hoffmann-La Roche Ltd launched Evrysdi (risdiplam) for the treatment of patient with spinal muscular atrophy in India

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets

This product will be delivered within 2 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Treatment
1.2.3. Route of Administration
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Spinal Muscular Atrophy Treatment Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
Chapter 4. Spinal Muscular Atrophy Treatment Market: Type Business Analysis
4.1. Type Market Share, 2024 & 2030
4.2. Type Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Billion)
4.4. Type 1
4.4.1. Type 1 Market, 2018 - 2030 (USD Billion)
4.5. Type 2
4.5.1. Type 2 Market, 2018 - 2030 (USD Billion)
4.6. Type 3
4.6.1. Type 3 Market, 2018 - 2030 (USD Billion)
4.7. Type 4
4.7.1. Type 4 Market, 2018 - 2030 (USD Billion)
Chapter 5. Spinal Muscular Atrophy Treatment Market: Treatment Business Analysis
5.1. Treatment Market Share, 2024 & 2030
5.2. Treatment Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Billion)
5.4. Gene Therapy
5.4.1. Gene Therapy Market, 2018 - 2030 (USD Billion)
5.5. Drug
5.5.1. Drug Market, 2018 - 2030 (USD Billion)
5.5.2. Spinraza
5.5.2.1. Spinraza Market, 2018 - 2030 (USD Billion)
5.5.3. Zolgensma (AVXS-101)
5.5.3.1. Zolgensma (AVXS-101) Market, 2018 - 2030 (USD Billion)
5.5.4. Evrysdi
5.5.4.1. Evrysdi Market, 2018 - 2030 (USD Billion)
5.5.5. Others
5.5.5.1. Others Market, 2018 - 2030 (USD Billion)
Chapter 6. Spinal Muscular Atrophy Treatment Market: Route of Administration Business Analysis
6.1. Route of Administration Market Share, 2024 & 2030
6.2. Route of Administration Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Billion)
6.4. Oral
6.4.1. Oral Market, 2018 - 2030 (USD Billion)
6.5. Injection
6.5.1. Injection Market, 2018 - 2030 (USD Billion)
Chapter 7. Spinal Muscular Atrophy Treatment Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
7.4. North America
7.4.1. North America Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Regulatory Framework
7.4.2.3. Competitive Insights
7.4.2.4. U.S. Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Regulatory Framework
7.4.3.3. Competitive Insights
7.4.3.4. Canada Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.4.4. Mexico
7.4.4.1. Key Country Dynamics
7.4.4.2. Regulatory Framework
7.4.4.3. Competitive Insights
7.4.4.4. Mexico Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5. Europe
7.5.1. Europe Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
7.5.2. UK
7.5.2.1. Key Country Dynamics
7.5.2.2. Regulatory Framework
7.5.2.3. Competitive Insights
7.5.2.4. UK Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.3. Germany
7.5.3.1. Key Country Dynamics
7.5.3.2. Regulatory Framework
7.5.3.3. Competitive Insights
7.5.3.4. Germany Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.4. France
7.5.4.1. Key Country Dynamics
7.5.4.2. Regulatory Framework
7.5.4.3. Competitive Insights
7.5.4.4. France Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.5. Italy
7.5.5.1. Key Country Dynamics
7.5.5.2. Regulatory Framework
7.5.5.3. Competitive Insights
7.5.5.4. Italy Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.6. Spain
7.5.6.1. Key Country Dynamics
7.5.6.2. Regulatory Framework
7.5.6.3. Competitive Insights
7.5.6.4. Spain Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.7. Norway
7.5.7.1. Key Country Dynamics
7.5.7.2. Regulatory Framework
7.5.7.3. Competitive Insights
7.5.7.4. Norway Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.8. Denmark
7.5.8.1. Key Country Dynamics
7.5.8.2. Regulatory Framework
7.5.8.3. Competitive Insights
7.5.8.4. Denmark Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.9. Sweden
7.5.9.1. Key Country Dynamics
7.5.9.2. Regulatory Framework
7.5.9.3. Competitive Insights
7.5.9.4. Sweden Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
7.6. Asia Pacific
7.6.1. Asia Pacific Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.6.2. Japan
7.6.2.1. Key Country Dynamics
7.6.2.2. Regulatory Framework
7.6.2.3. Competitive Insights
7.6.2.4. Japan Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.6.3. China
7.6.3.1. Key Country Dynamics
7.6.3.2. Regulatory Framework
7.6.3.3. Competitive Insights
7.6.3.4. China Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.6.4. India
7.6.4.1. Key Country Dynamics
7.6.4.2. Regulatory Framework
7.6.4.3. Competitive Insights
7.6.4.4. India Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.6.5. South Korea
7.6.5.1. Key Country Dynamics
7.6.5.2. Regulatory Framework
7.6.5.3. Competitive Insights
7.6.5.4. South Korea Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.6.6. Australia
7.6.6.1. Key Country Dynamics
7.6.6.2. Regulatory Framework
7.6.6.3. Competitive Insights
7.6.6.4. Australia Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.6.7. Thailand
7.6.7.1. Key Country Dynamics
7.6.7.2. Regulatory Framework
7.6.7.3. Competitive Insights
7.6.7.4. Thailand Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.7. Latin America
7.7.1. Latin America Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
7.7.2. Brazil
7.7.2.1. Key Country Dynamics
7.7.2.2. Regulatory Framework
7.7.2.3. Competitive Insights
7.7.2.4. Brazil Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.7.3. Argentina
7.7.3.1. Key Country Dynamics
7.7.3.2. Regulatory Framework
7.7.3.3. Competitive Insights
7.7.3.4. Argentina Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.8. MEA
7.8.1. MEA Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
7.8.2. South Africa
7.8.2.1. Key Country Dynamics
7.8.2.2. Regulatory Framework
7.8.2.3. Competitive Insights
7.8.2.4. South Africa Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.8.3. Saudi Arabia
7.8.3.1. Key Country Dynamics
7.8.3.2. Regulatory Framework
7.8.3.3. Competitive Insights
7.8.3.4. Saudi Arabia Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.8.4. UAE
7.8.4.1. Key Country Dynamics
7.8.4.2. Regulatory Framework
7.8.4.3. Competitive Insights
7.8.4.4. UAE Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.8.5. Kuwait
7.8.5.1. Key Country Dynamics
7.8.5.2. Regulatory Framework
7.8.5.3. Competitive Insights
7.8.5.4. Kuwait Spinal Muscular Atrophy Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
Chapter 8. Competitive Landscape
8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
8.5.1. Biogen
8.5.1.1. Overview
8.5.1.2. Financial Performance
8.5.1.3. Product Benchmarking
8.5.1.4. Strategic Initiatives
8.5.2. Novartis AG
8.5.2.1. Overview
8.5.2.2. Financial Performance
8.5.2.3. Product Benchmarking
8.5.2.4. Strategic Initiatives
8.5.3. Pfizer Inc.
8.5.3.1. Overview
8.5.3.2. Financial Performance
8.5.3.3. Product Benchmarking
8.5.3.4. Strategic Initiatives
8.5.4. Ionis Pharmaceuticals
8.5.4.1. Overview
8.5.4.2. Financial Performance
8.5.4.3. Product Benchmarking
8.5.4.4. Strategic Initiatives
8.5.5. Biohaven, Ltd.
8.5.5.1. Overview
8.5.5.2. Financial Performance
8.5.5.3. Product Benchmarking
8.5.5.4. Strategic Initiatives
8.5.6. F. Hoffmann-La Roche Ltd
8.5.6.1. Overview
8.5.6.2. Financial Performance
8.5.6.3. Product Benchmarking
8.5.6.4. Strategic Initiatives
8.5.7. Cytokinetics
8.5.7.1. Overview
8.5.7.2. Financial Performance
8.5.7.3. Product Benchmarking
8.5.7.4. Strategic Initiatives
8.5.8. Scholar Rock, Inc.
8.5.8.1. Overview
8.5.8.2. Financial Performance
8.5.8.3. Product Benchmarking
8.5.8.4. Strategic Initiatives
8.5.9. PTC Therapeutics
8.5.9.1. Overview
8.5.9.2. Financial Performance
8.5.9.3. Product Benchmarking
8.5.9.4. Strategic Initiatives
8.5.10. NMD PHARMA A/S
8.5.10.1. Overview
8.5.10.2. Financial Performance
8.5.10.3. Product Benchmarking
8.5.10.4. Strategic Initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global spinal muscular atrophy treatment market, by region, 2018 - 2030 (USD Billion)
Table 4 Global spinal muscular atrophy treatment market, by type, 2018 - 2030 (USD Billion)
Table 5 Global spinal muscular atrophy treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 6 Global spinal muscular atrophy treatment market, by route of administration, 2018 - 2030 (USD Billion)
Table 7 North America spinal muscular atrophy treatment market, by country, 2018 - 2030 (USD Billion)
Table 8 North America spinal muscular atrophy treatment market, by type, 2018 - 2030 (USD Billion)
Table 9 North America spinal muscular atrophy treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 10 North America spinal muscular atrophy treatment market, by route of administration, 2018 - 2030 (USD Billion)
Table 11 U.S. spinal muscular atrophy treatment market, by type, 2018 - 2030 (USD Billion)
Table 12 U.S. spinal muscular atrophy treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 13 U.S. spinal muscular atrophy treatment market, by route of administration, 2018 - 2030 (USD Billion)
Table 14 Canada spinal muscular atrophy treatment market, by type, 2018 - 2030 (USD Billion)
Table 15 Canada spinal muscular atrophy treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 16 Canada spinal muscular atrophy treatment market, by route of administration, 2018 - 2030 (USD Billion)
Table 17 Mexico spinal muscular atrophy treatment market, by type, 2018 - 2030 (USD Billion)
Table 18 Mexico spinal muscular atrophy treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 19 Mexico spinal muscular atrophy treatment market, by route of administration, 2018 - 2030 (USD Billion)
Table 20 Europe spinal muscular atrophy treatment market, by country, 2018 - 2030 (USD Billion)
Table 21 Europe spinal muscular atrophy treatment market, by type, 2018 - 2030 (USD Billion)
Table 22 Europe spinal muscular atrophy treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 23 Europe spinal muscular atrophy treatment market, by route of administration, 2018 - 2030 (USD Billion)
Table 24 UK spinal muscular atrophy treatment market, by type, 2018 - 2030 (USD Billion)
Table 25 UK spinal muscular atrophy treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 26 UK spinal muscular atrophy treatment market, by route of administration, 2018 - 2030 (USD Billion)
Table 27 Germany spinal muscular atrophy treatment market, by type, 2018 - 2030 (USD Billion)
Table 28 Germany spinal muscular atrophy treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 29 Germany spinal muscular atrophy treatment market, by route of administration, 2018 - 2030 (USD Billion)
Table 30 France spinal muscular atrophy treatment market, by type, 2018 - 2030 (USD Billion)
Table 31 France spinal muscular atrophy treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 32 France spinal muscular atrophy treatment market, by route of administration, 2018 - 2030 (USD Billion)
Table 33 Italy spinal muscular atrophy treatment market, by type, 2018 - 2030 (USD Billion)
Table 34 Italy spinal muscular atrophy treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 35 Italy spinal muscular atrophy treatment market, by route of administration, 2018 - 2030 (USD Billion)
Table 36 Spain spinal muscular atrophy treatment market, by type, 2018 - 2030 (USD Billion)
Table 37 Spain spinal muscular atrophy treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 38 Spain spinal muscular atrophy treatment market, by route of administration, 2018 - 2030 (USD Billion)
Table 39 Norway spinal muscular atrophy treatment market, by type, 2018 - 2030 (USD Billion)
Table 40 Norway spinal muscular atrophy treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 41 Norway spinal muscular atrophy treatment market, by route of administration, 2018 - 2030 (USD Billion)
Table 42 Denmark spinal muscular atrophy treatment market, by type, 2018 - 2030 (USD Billion)
Table 43 Denmark spinal muscular atrophy treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 44 Denmark spinal muscular atrophy treatment market, by route of administration, 2018 - 2030 (USD Billion)
Table 45 Sweden spinal muscular atrophy treatment market, by type, 2018 - 2030 (USD Billion)
Table 46 Sweden spinal muscular atrophy treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 47 Sweden spinal muscular atrophy treatment market, by route of administration, 2018 - 2030 (USD Billion)
Table 48 Asia Pacific spinal muscular atrophy treatment market, by country, 2018 - 2030 (USD Billion)
Table 49 Asia Pacific spinal muscular atrophy treatment market, by type, 2018 - 2030 (USD Billion)
Table 50 Asia Pacific spinal muscular atrophy treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 51 Asia Pacific spinal muscular atrophy treatment market, by route of administration, 2018 - 2030 (USD Billion)
Table 52 Japan spinal muscular atrophy treatment market, by type, 2018 - 2030 (USD Billion)
Table 53 Japan spinal muscular atrophy treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 54 Japan spinal muscular atrophy treatment market, by route of administration, 2018 - 2030 (USD Billion)
Table 55 China spinal muscular atrophy treatment market, by type, 2018 - 2030 (USD Billion)
Table 56 China spinal muscular atrophy treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 57 China spinal muscular atrophy treatment market, by route of administration, 2018 - 2030 (USD Billion)
Table 58 India spinal muscular atrophy treatment market, by type, 2018 - 2030 (USD Billion)
Table 59 India spinal muscular atrophy treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 60 India spinal muscular atrophy treatment market, by route of administration, 2018 - 2030 (USD Billion)
Table 61 Australia spinal muscular atrophy treatment market, by type, 2018 - 2030 (USD Billion)
Table 62 Australia spinal muscular atrophy treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 63 Australia spinal muscular atrophy treatment market, by route of administration, 2018 - 2030 (USD Billion)
Table 64 South Korea spinal muscular atrophy treatment market, by type, 2018 - 2030 (USD Billion)
Table 65 South Korea spinal muscular atrophy treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 66 South Korea spinal muscular atrophy treatment market, by route of administration, 2018 - 2030 (USD Billion)
Table 67 Thailand spinal muscular atrophy treatment market, by type, 2018 - 2030 (USD Billion)
Table 68 Thailand spinal muscular atrophy treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 69 Thailand spinal muscular atrophy treatment market, by route of administration, 2018 - 2030 (USD Billion)
Table 70 Latin America spinal muscular atrophy treatment market, by country, 2018 - 2030 (USD Billion)
Table 71 Latin America spinal muscular atrophy treatment market, by type, 2018 - 2030 (USD Billion)
Table 72 Latin America spinal muscular atrophy treatment market, by treatment, 2018 - 2030 (USD Billion
Table 73 Latin America spinal muscular atrophy treatment market, by route of administration, 2018 - 2030 (USD Billion
Table 74 Brazil spinal muscular atrophy treatment market, by type, 2018 - 2030 (USD Billion)
Table 75 Brazil spinal muscular atrophy treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 76 Brazil spinal muscular atrophy treatment market, by route of administration, 2018 - 2030 (USD Billion)
Table 77 Argentina spinal muscular atrophy treatment market, by type, 2018 - 2030 (USD Billion)
Table 78 Argentina spinal muscular atrophy treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 79 Argentina spinal muscular atrophy treatment market, by route of administration, 2018 - 2030 (USD Billion)
Table 80 Middle East & Africa spinal muscular atrophy treatment market, by country, 2018 - 2030 (USD Billion)
Table 81 Middle East & Africa spinal muscular atrophy treatment market, by type, 2018 - 2030 (USD Billion)
Table 82 Middle East & Africa spinal muscular atrophy treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 83 Middle East & Africa spinal muscular atrophy treatment market, by route of administration, 2018 - 2030 (USD Billion)
Table 84 South Africa spinal muscular atrophy treatment market, by type, 2018 - 2030 (USD Billion)
Table 85 South Africa spinal muscular atrophy treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 86 South Africa spinal muscular atrophy treatment market, by route of administration, 2018 - 2030 (USD Billion)
Table 87 Saudi Arabia spinal muscular atrophy treatment market, by type, 2018 - 2030 (USD Billion)
Table 88 Saudi Arabia spinal muscular atrophy treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 89 Saudi Arabia spinal muscular atrophy treatment market, by route of administration, 2018 - 2030 (USD Billion)
Table 90 UAE spinal muscular atrophy treatment market, by type, 2018 - 2030 (USD Billion)
Table 91 UAE spinal muscular atrophy treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 92 UAE spinal muscular atrophy treatment market, by route of administration, 2018 - 2030 (USD Billion)
Table 93 Kuwait spinal muscular atrophy treatment market, by type, 2018 - 2030 (USD Billion)
Table 94 Kuwait spinal muscular atrophy treatment market, by treatment, 2018 - 2030 (USD Billion)
Table 95 Kuwait spinal muscular atrophy treatment market, by route of administration, 2018 - 2030 (USD Billion)
List of Figures
Fig. 1 Spinal muscular atrophy treatment market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Type outlook (USD Billion)
Fig. 10 Treatment outlook (USD Billion)
Fig. 11 Route of administration outlook (USD Billion)
Fig. 12 Competitive landscape
Fig. 13 Spinal muscular atrophy treatment market dynamics
Fig. 14 Spinal muscular atrophy treatment market: Porter’s five forces analysis
Fig. 15 Spinal muscular atrophy treatment market: PESTLE analysis
Fig. 16 Spinal muscular atrophy treatment market: Type segment dashboard
Fig. 17 Spinal muscular atrophy treatment market: Type market share analysis, 2024 & 2030
Fig. 18 Type 1 market, 2018 - 2030 (USD Billion)
Fig. 19 Type 2 market, 2018 - 2030 (USD Billion)
Fig. 20 Type 3 market, 2018 - 2030 (USD Billion)
Fig. 21 Type 4 market, 2018 - 2030 (USD Billion)
Fig. 22 Spinal muscular atrophy treatment market: Treatment segment dashboard
Fig. 23 Spinal muscular atrophy treatment market: Treatment market share analysis, 2024 & 2030
Fig. 24 Gene therapy market, 2018 - 2030 (USD Billion)
Fig. 25 Drug market, 2018 - 2030 (USD Billion)
Fig. 26 Spinraza market, 2018 - 2030 (USD Billion)
Fig. 27 Zolgensma (AVXS-101) market, 2018 - 2030 (USD Billion)
Fig. 28 Evrysdi market, 2018 - 2030 (USD Billion)
Fig. 29 Others market, 2018 - 2030 (USD Billion)
Fig. 30 Spinal muscular atrophy treatment market: Route of administration segment dashboard
Fig. 31 Spinal muscular atrophy treatment market: Route of administration market share analysis, 2024 & 2030
Fig. 32 Oral market, 2018 - 2030 (USD Billion)
Fig. 33 Injection market, 2018 - 2030 (USD Billion)
Fig. 34 Spinal muscular atrophy treatment market revenue, by region
Fig. 35 Regional marketplace: Key takeaways
Fig. 36 North America spinal muscular atrophy treatment market, 2018 - 2030 (USD Billion)
Fig. 37 U.S. country dynamics
Fig. 38 U.S. spinal muscular atrophy treatment market, 2018 - 2030 (USD Billion)
Fig. 39 Canada country dynamics
Fig. 40 Canada spinal muscular atrophy treatment market, 2018 - 2030 (USD Billion)
Fig. 41 Mexico country dynamics
Fig. 42 Mexico spinal muscular atrophy treatment market, 2018 - 2030 (USD Billion)
Fig. 43 Europe spinal muscular atrophy treatment market, 2018 - 2030 (USD Billion)
Fig. 44 UK country dynamics
Fig. 45 UK spinal muscular atrophy treatment market, 2018 - 2030 (USD Billion)
Fig. 46 Germany country dynamics
Fig. 47 Germany spinal muscular atrophy treatment market, 2018 - 2030 (USD Billion)
Fig. 48 France country dynamics
Fig. 49 France spinal muscular atrophy treatment market, 2018 - 2030 (USD Billion)
Fig. 50 Italy country dynamics
Fig. 51 Italy spinal muscular atrophy treatment market, 2018 - 2030 (USD Billion)
Fig. 52 Spain country dynamics
Fig. 53 Spain spinal muscular atrophy treatment market, 2018 - 2030 (USD Billion)
Fig. 54 Norway country dynamics
Fig. 55 Norway spinal muscular atrophy treatment market, 2018 - 2030 (USD Billion)
Fig. 56 Denmark country dynamics
Fig. 57 Denmark spinal muscular atrophy treatment market, 2018 - 2030 (USD Billion
Fig. 58 Sweden country dynamics
Fig. 59 Sweden spinal muscular atrophy treatment market, 2018 - 2030 (USD Billion)
Fig. 60 Asia Pacific spinal muscular atrophy treatment market, 2018 - 2030 (USD Billion)
Fig. 61 Japan country dynamics
Fig. 62 Japan spinal muscular atrophy treatment market, 2018 - 2030 (USD Billion)
Fig. 63 China country dynamics
Fig. 64 China spinal muscular atrophy treatment market, 2018 - 2030 (USD Billion)
Fig. 65 India country dynamics
Fig. 66 India spinal muscular atrophy treatment market, 2018 - 2030 (USD Billion)
Fig. 67 South Korea country dynamics
Fig. 68 South Korea spinal muscular atrophy treatment market, 2018 - 2030 (USD Billion)
Fig. 69 Australia country dynamics
Fig. 70 Australia spinal muscular atrophy treatment market, 2018 - 2030 (USD Billion)
Fig. 71 Thailand country dynamics
Fig. 72 Thailand spinal muscular atrophy treatment market, 2018 - 2030 (USD Billion)
Fig. 73 Latin America spinal muscular atrophy treatment market, 2018 - 2030 (USD Billion)
Fig. 74 Brazil country dynamics
Fig. 75 Brazil spinal muscular atrophy treatment market, 2018 - 2030 (USD Billion)
Fig. 76 Argentina country dynamics
Fig. 77 Argentina spinal muscular atrophy treatment market, 2018 - 2030 (USD Billion)
Fig. 78 MEA spinal muscular atrophy treatment market, 2018 - 2030 (USD Billion)
Fig. 79 South Africa country dynamics
Fig. 80 South Africa spinal muscular atrophy treatment market, 2018 - 2030 (USD Billion)
Fig. 81 Saudi Arabia country dynamics
Fig. 82 Saudi Arabia spinal muscular atrophy treatment market, 2018 - 2030 (USD Billion)
Fig. 83 UAE country dynamics
Fig. 84 UAE spinal muscular atrophy treatment market, 2018 - 2030 (USD Billion)
Fig. 85 Kuwait country dynamics
Fig. 86 Kuwait spinal muscular atrophy treatment market, 2018 - 2030 (USD Billion)
Fig. 87 Company categorization
Fig. 88 Company market position analysis
Fig. 89 Strategic framework

Companies Mentioned

  • Biogen
  • Novartis AG
  • Pfizer Inc.
  • Ionis Pharmaceuticals
  • Biohaven, Ltd.
  • F. Hoffmann-La Roche Ltd
  • Cytokinetics
  • Scholar Rock, Inc.
  • PTC Therapeutics
  • NMD PHARMA A/S

Methodology

Loading
LOADING...

Table Information